



ASX Announcement

RESULTS OF 2022 ANNUAL STOCKHOLDERS MEETING

4 May 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) refers to the Annual Stockholders Meeting held today. The results of the meeting are set out in the attached document in accordance with ASX Listing Rule 3.13.2. All resolutions were decided and passed by way of a poll.

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor expects to sell its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.



Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Results of meeting

Name of entity

Imricor Medical Systems, Inc.

ARBN

633 106 019

Date of meeting

4 May 2022 Australian time (3 May 2022 US time)

Resolutions voted on at the meeting					If decided by poll ⁵				Proxies received ⁶				
Resolution		Result ²	Voting method ³	If s250U applies ⁴	Voted for		Voted against		Abstained	For	Against	Abstain	Discretion ⁹
No ¹	Short description				Number	% ⁷	Number	% ⁸	Number	Number	Number	Number	Number
1	Election of Class III Director – Mr Peter McGregor	Passed	Poll	N/A	40,807,934	99.26	302,886 (withheld)	0.74	-	39,752,151	-	302,886 (withheld)	-
2	Ratification and approval of prior issue of CDIs under the September Placement	Passed	Poll	N/A	30,722,803	74.73	381,596	0.93	10,006,421	30,046,616	2,000	10,006,421	-
3	Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company	Passed	Poll	N/A	29,356,202	79.98	7,316,610	19.93	33,275	28,300,419	7,316,610	33,275	-
4	Grant of Restricted Stock Award to Mr Peter McGregor, Non-Executive Director of the Company	Passed	Poll	N/A	23,941,567	65.23	12,731,245	34.68	33,275	22,948,284	12,668,745	33,275	-
5	Grant of Restricted Stock Award to Ms Anita Messal, Non-Executive Director of the Company	Passed	Poll	N/A	23,941,567	65.23	12,731,245	34.68	33,275	22,948,284	12,668,745	33,275	-
6	Grant of Restricted Stock Award to Mr Mark Tibbles, Non-Executive Director of the Company	Passed	Poll	N/A	22,245,012	60.61	12,731,245	34.68	1,729,830	21,251,729	12,668,745	1,729,830	-
7	Approval of 10% Placement Facility	Passed	Poll	N/A	40,742,551	99.10	-	-	368,269	39,893,268	-	161,769	-

Resolutions proposed but not put to the meeting¹⁰		
No¹	Short description	Reason(s) for not putting the resolution to the meeting

Instructions:

1. The resolution numbers in the tables above should match the resolution numbers in the notice of meeting.
2. Insert "Passed" or "Not passed", as appropriate.
3. Insert "Poll" or "Show of hands", as appropriate.
4. Insert "1st strike", "2nd strike" or "N/A", as appropriate.
5. Complete this section if the resolution was decided by a poll. Ignore this section if the resolution was decided by a show of hands.
6. Complete this section for all resolutions, showing the number of valid proxies received and how the proxy was directed to vote on the resolution.
7. Calculate this percentage as the number of votes cast for the resolution, divided by the total number of votes cast on the resolution. When summed with the percentage voted against the resolution, this should add to 100%.
8. Calculate this percentage as the number of votes cast against the resolution, divided by the total number of votes cast on the resolution. When summed with the percentage voted for the resolution, this should add to 100%.
9. "Discretion" means the proxy could vote on the resolution in their discretion.
10. Delete this table if there were no resolutions proposed but not put to the meeting.
11. Add or remove rows from each table to accommodate the number of resolutions proposed in the notice of meeting.
12. Delete these instructions before submitting this form to ASX.
13. See Guidance Note 35 *Security Holder Resolutions* for further guidance.